RT info:eu-repo/semantics/article
T1 Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
A1 Sanz-Solas, Antonio
A1 Labrador, Jorge
A1 Alcaraz, Raquel
A1 Cuevas, Beatriz
A1 Vinuesa, Raquel
A1 Cuevas, María Victoria
A1 Saiz-Rodríguez, Miriam
K1 Multiple myeloma
K1 Bortezomib
K1 Toxicity
K1 Efficacy
K1 Pharmacogenetic biomarkers
K1 Farmacogenómica
K1 Pharmacogenomics
AB Multiple myeloma (MM) is a hematological neoplasm for which different chemotherapy treatments are used with several drugs in combination. One of the most frequently used drugs for the treatment of MM is the proteasome inhibitor bortezomib. Patients treated with bortezomib are at increased risk for thrombocytopenia, neutropenia, gastrointestinal toxicities, peripheral neuropathy, infection, and fatigue. This drug is almost entirely metabolized by cytochrome CYP450 isoenzymes and transported by the efflux pump P-glycoprotein. Genes encoding both enzymes and transporters involved in the bortezomib pharmacokinetic pathway are highly polymorphic. The response to bortezomib and the incidence of adverse drug reactions (ADRs) vary among patients, which could be due to interindividual variations in these possible pharmacogenetic biomarkers. In this review, we compiled all pharmacogenetic information relevant to the treatment of MM with bortezomib. In addition, we discuss possible future perspectives and the analysis of potential pharmacogenetic markers that could influence the incidence of ADR and the toxicity of bortezomib. It would be a milestone in the field of targeted therapy for MM to relate potential biomarkers to the various effects of bortezomib on patients.
PB MDPI
SN 2075-4426
YR 2023
FD 2023-04
LK https://hdl.handle.net/10259/11919
UL https://hdl.handle.net/10259/11919
LA eng
NO A.S.-S. contract was funded by Fundación hna, 2nd edition of the Scientific Health Research Award. M.S.-R. contract was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation, through the Sara Borrell Program (CD21/00022).
DS Repositorio Institucional de la Universidad de Burgos
RD 18-jul-2026